Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: Relation to azathioprine maintenance treatment and adverse effects

Annals of the Rheumatic Diseases

Volumn 68, Issue 5, 2009, Pages 758-759

  Stassen, P M ^a,b   Derks, R P H ^a   Kallenberg, C G M ^a   Stegeman, C A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; THIOPURINE METHYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ALLELE; ANCA ASSOCIATED VASCULITIS; ANEMIA; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEPATITIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY GRAFT; LETTER; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTOPENIA; WEGENER GRANULOMATOSIS; GENETICS; TREATMENT OUTCOME; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULITIS;

EID: 66149089224     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097667     Document Type: Letter

References (10)

1. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20. (Pubitemid 26230808)
2. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-614 (Pubitemid 27172187)
3. Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998;54:265-271 (Pubitemid 28288301)
4. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-670 (Pubitemid 32989203)
5. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, Domanski L, Drozdzik M. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther Drug Monit 2005;27:435-441 (Pubitemid 41098817)
6. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-1750
7. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-417 (Pubitemid 38561239)
8. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:593-599 (Pubitemid 39279046)
9. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-2512 (Pubitemid 35416953)
10. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007;32:187-195 (Pubitemid 46449703)